The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation

Current Topics in Medicinal Chemistry

Volumn 5, Issue 2, 2005, Pages 109-125

  Barnett, Stanley F ^a   Bilodeau, Mark T ^a   Lindsley, Craig W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt. PKB; Allosteric; Apoptosis; Cancer; Chemotherapy; Inhibitors; Kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AAL 993; ANTINEOPLASTIC AGENT; API 2; BALANOL; BISINDOLYLMALEIMIDE; CAMPTOTHECIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 1; DORAMAPIMOD; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMATINIB; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NL 71 101; PEPTIDE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PLECKSTRIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; QUINOXALINE DERIVATIVE; SR 13668; STAT PROTEIN; STAUROSPORINE; TRANSCRIPTION FACTOR FKHRL1; TRASTUZUMAB; TRICIRIBINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HYPERGLYCEMIA; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CARCINOMA; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17144392548     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026053507714     Document Type: Review

References (107)

1. Luo, J.; Manning, B. D.; Cantley, L. C. Targeting the P13K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4, 257-262.
2. Lu, Y,; Wang, H,; Mills, G. B. Targeting PI3K-AKT pathway for cancer therapy. Rev. Clin. Exp. Hematol. 2003, 7, 205-228.
3. Mitsiades, C. S.; Mitsiades, N.; Koutsilieris, M.; Nicholson, K. M.; Anderson, N. G.; Neri, L. M.; Borgatti, P.; Capitani, S.; Martelli, A. M.; Brazil, D. P.; Hemmings, B. A. The Akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets 2004, 4, 235-256.
4. Vivanco, I; Sawyers, C. L. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nature Rev. 2002, 2 489-501.
5. Brazil, D. P.; Hemmings, B. A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends in Biochem. Sci. 2001 26 (11), 657-664.
6. Simpson, L.; Parsons, R. PTEN: Life as a tumor suppressor. Experi. Cell Res. 2001, 264, 29-41.
7. Vanhaesebroeck, B.; Alessi, D. R. The P13K-PDK1 connection: more than just a road to PKB. Biochem. J. 2000, 346, 561-576.
8. Besson, A.; Robbins, S. M.; Yong, V. W. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Euro. J. Biochem. 1999 263, 605-611.
9. Chan, T. O.; Rittenhouse, S. E.; Tsichlis, P. N. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. An. Rev. Biochem. 1999, 68, 965-1014.
10. Alessi, D. R.; Cohen, P. Mechanism of activation and function of protein kinase B. Cur. Opin. Genet. Develop. 1998, 8 55-62.
11. Sulis, M. L.; Parsons, R. PTEN: from pathology to biology. Trends Cell Biol. 2003, 13, 478-483.
12. Bonneau, D.; Longy, M. Mutations of the human PTEN gene. Human Mutation 2000, 16, 109-122.
13. Yeh, J. J.; Sellers, W. R. PTEN - Regulator of phosphoinositide 3-kinase signal transduction. Tumor Suppressor Genes in Human Cancer; Humana Press Inc: Totowa, 2000; pp 231-251.
14. Derrey, S.; Proust, F.; Debono, B.; Langlois, O.; Layet, A.; Layet, V.; Longy, M.; Freger, P.; Laquerriere, A. Association between Cowden syndrome and Lhermitte-Duclos disease: report of two cases and review of the literature. Surg. Neurol. 2004, 61, 447-454.
15. Pilarski, R.; Eng, C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J. Med Genet. 2004, 41, 323-326.
16. Hendriks, Y. M.; Verhallen, J. T.; van-der-Smagt, J. J.; Kant, S. G.; Hilhorst, Y.; Hoefsloot, L.; Hansson, K. B.; van-der-Straaten, P. J.; Boutkan, H.; Breuning, M. H.; Vasen. H. F.; Brocker-Vriends. A. H. Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases. Fam Cancer 2003, 2, 79-85.
17. Zhou, X. P.; Marsh, D. J.; Morrison, C. D.; Chaudhury, A. R.; Maxwell, M.; Reifenberger, G.; Eng, C. Germline Inactivation of PTEN and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway Cause Human Lhermitte-Duclos Disease in Adults. Am. J. Hum. Genet. 2003, 73, 1191-1198.
18. Chang, F.; Lee, J. T.; Navolanic, P. M.; Steelman, L. S.; Shelton, J. G.; Blalock, W. L.; Franklin, R. A.; McCubrey, J. A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17, 590-603.
19. Fresno-Vara, J. A.; Casado, E.; de-Castro, J.; Cejas, P.; Belda-Iniesta, C.; Gonzalez-Baron, M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30, 193-204.
20. Paweletz, C. P.; Charboneau, L.; Bichsel, V. E.; Simone, N. L.; Chen, T.; Gillespie, J. W.; Emmert Buck, M. R.; Roth, M. J.; Petricoin, E. F.; Liotta, L. A. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20, 1981-1989.
21. Malik, S. N.; Brattain, M.; Ghosh, P. M.; Troyer, D. A.; Prihoda, T.; Bedolla, R.; Kreisberg, J. I. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 2002, 8 (4), 1168-1171.
22. Dhawan, P.; Singh, A. B.; Ellis, D. L.; Richmond, A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 2002, 62, 7335-7342.
23. Vasko, V.; Saji, M.; Hardy, E.; Kruhlak, M.; Latin, A.; Savchenko, V.; Miyakawa, M.; Isozaki, O.; Murakami, H.; Tsushima, T.; Burman, K. D.; De-Micco, C.; Ringel, M. D. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet. 2004, 41, 161-170.
24. Itoh, N.; Semba, S.; Ito, M.; Takeda, H.; Kawata, S.; Yamakawa, M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002, 94 (12), 3127-3134.
25. Roy, H. K.; Olusola, B. F.; Clemens, D. L.; Karolski, W. J.; Ratashak, A.; Lynch, H. T.; Smyrk, T. C. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002, 23 (1), 201-205.
26. Shi, W.; Zhang, X.; Pintilie, M.; Ma, N.; Miller, N.; Banerjee, D.; Tsao, M. S.; Mak, T.; Fyles, A.; Liu, F. F. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int. J. Cancer 2003, 104, 195-203.
27. Vara, J. A. F.; Casado, E.; de Castro, J.; Cejas, P.; Belda Iniesta, C.; Gonzalez Baron, M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30, 193-204.
28. Tsuruo, T,; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94, 15-21.
29. Frolov, A.; Chahwan, S.; Ochs, M.; Arnoletti, J. P.; Pan, Z. Z.; Favorova, O.; Fletcher, J., von Meliren, M.; Eisenberg, B.; Godwin, A. K. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol. Cancer Ther. 2003, 2, 699-709.
30. Ohashi, A.; Kinoshita, K.; Isozaki, K.; Nishida, T.; Shinomura, Y.; Kitamura, Y.; Hirota, S. Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. Inter. J. Cancer 2004, 111, 317-321.
31. Kawauchi, K.; Ogasawara, T.; Yasuyama, M.; Ohkawa, S. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol. Dis. 2003, 31, 11-17.
32. Klos, K. S.; Zhou, X,; Lee, S.; Zhang, L.; Yang, W.; Nagata, Y.; Yu, D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003, 98, 1377-1385.
33. Yakes, F. M.; Chinratanalab, W.; Ritter, C. A.; King, W.; Seelig, S.; Arteaga, C. L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62, 4132-4141.
34. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1, 707-717.
35. Ono, M.; Hirata, A.; Kometani, T.; Miyagawa, M.; Ueda, S.; Kinoshita, H.; Fujii, T.; Kuwano, M. Sensitivity to gefitinib (Iressa, ZDI839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Thera. 2004, 3, 465-472.
36. Janmaat, M. L.; Kruyt, F. A. E.; Rodriguez, J. A.; Giaccone, G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 2003, 9, 2316-2326.
37. Cappuzzo, F.; Magrini, E.; Ceresoli, G. L.; Bartolini, S.; Rossi, E.; Ludovini, V.; Gregorc, V.; Ligorio, C.; Cancellieri, A.; Damiani, S.; Spreafico, A.; Paties, C. T.; Lombardo, L.; Calandri, C.; Bellezza, G.; Tonato, M.; Crino, L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 2004, 96, 1133-1141.
38. Daneshmand, M.; Parolin, D. A. E.; Hirte, H. W.; Major, P.; Goss, G.; Stewart, D.; Batist, G.; Miller, W. H.; Matthews, S.; Seymour, L.; Lorimer, I. A. J. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin. Cancer Res. 2003, 9, 2457-2464.
39. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163-1167.
40. Pao, W.; Miller, V. A.; Venkatraman, E.; Kris, M. G. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? J. Natl. Cancer Inst. 2004, 96, 1117-1119.
41. Laine, J.; Kunstle, G.; Obata, T.; Noguchi, M. Differential regulation of Akt kinase isoforms by the members of TCL1 oncogene family. J. Biol. Chem. 2002, 277, 3743-3751.
42. Cho, H.; Thorvaldsen, J. L.; Chu, Q. W.; Feng, F.; Birnbaum, M. J. Akt1/PKB alpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 2001 276, 38349-38352.
43. Garofalo, R. S.; Orena, S. J.; Rafidi, K.; Torchia, A. J.; Stock, J. L.; Hildebrandt, A. L.; Coskran, T.; Black, S. C.; Brees, D. J.; Wicks, J. R.; McNeish, J. D.; Coleman, K, G. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J. Clin. Invest. 2003, 112, 197-208.
44. Cho, H.; Mu, J.; Kim, J. K.; Thorvaldsen, J. L.; Chu, Q. W.; Crenshaw, E. B.; Kaestner, K. H.; Bartolomei, M. S.; Shulman, G. I.; Birnbaum, M. J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001 292, 1728-1731.
45. Page, C.; Lin, H. J.; Jin, Y.; Castle, V. P.; Nunez, G.; Huang, M.; Lin, J. Y. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 2000, 20 407-416.
46. Bellacosa, A.; DeFeo, D.; Godwin, A. K.; Bell, D. W.; Cheng, J. Q.; Altomare, D. A.; Wan, M. H.; Dubeau, L.; Scambia, G.; Masciullo, V.; Ferrandina, G.; Panici, P. B.; Mancuso, S.; Neri, G.; Testa, J. R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Inter. J. Cancer 1995, 64, 280-285.
47. Staal, S. P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification od AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad Sci. USA 1987, 84 5034-5037.
48. Stahl, J. M.; Sharma, A.; Cheung, M.; Zimmerman, M,; Cheng, J. Q.; Bosenberg, M. W.; Kester, M.; Sandirasegarane, L.; Robertson, G. P. Deregulated Akt3 Activity Promotes Development of Malignant Melanoma. Cancer Res. 2004, 64, 7002-7010.
49. Nakatani, K.; Thompson, D. A.; Barthel, A.; Sakaue, H.; Liu, W.; Weigel, R. J.; Roth, R. A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 1999, 274, 21528-21532.
50. Masure, S.; Haefner, B.; Wesselink, J. J.; Hoefnagel, E.; Mortier, E.; Verhasselt, P.; Tuytelaars, A.; Gordon, R.; Richardson, A. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Euro. J. Biochem. 1999, 265 353-360.
51. Istrail, S.; Sutton, G. G.; Florea, L.; Halpern, A. L.; Mobarry, C. M.; Lippert, R.; Walenz, B.; Shatkay, H.; Dew, I.; Miller, J. R.; Flanigan, M. J.; Edwards, N. J.; Bolanos, R.; Fasulo, D.; Halldorsson, B. V.; Hannenhalli, S.; Turner, R.; Yooseph, S.; Lu, F.; Nusskern, D. R.; Shue, B. C.; Zheng, X. H.; Zhong, F.; Delcher, A. L.; Huson, D. H.; Kravitz, S. A.; Mouchard, L.; Reinert, K.; Remington, K. A.; Clark, A. G.; Waterman, M. S.; Eichler, E. E.; Adams, M. D.; Hunkapiller, M. W.; Myers, E. W.; Venter, J. C. Whole-genome shotgun assembly and comparison of human genome assemblies. PNAS 2004 101, 1916-1921.
52. Bateman, A.; Coin, L.; Durbin, R.; Finn, R. D.; Hollich, V.; Griffiths-Jones, S.; Khanna, A.; Marshall, M.; Moxon, S.; Sonnhammer, E. L. L.; Studholme, D. J.; Yeats, C.; Eddy, S. R. The Pfam protein families database. Nucl. Acids. Res. 2004, 32, D138-141.
53. Frech, M.; Andjelkovic, M.; Ingley, E.; Reddy, K. K.; Falck, J. R.; Hemmings, B. A. High affinity binding of inositol phosphates and phosphoinositides to the Pleckstrin homology domain of RAC protein kinase B and their influence on kinase activity. J. Biol. Chem. 1997 272, 8474-8481.
54. James, S. R.; Downes, C. P.; Gigg, R.; Grove, S. J. A.; Holmes, A. B.; Alessi, D. R. Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-triphosphate without subsequent activation. Biochem. J. 1996, 315, 709-713.
55. Milburn, C. C.; Deak, M.; Kelly, S. M.; Price, N. C.; Alessi, D. R.; Van-Aalten, D. M. Binding of phosphatidylinositol 3,4,5-trisphosphate to +the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. J. 2003, 375 531-538.
56. Thomas, C. C.; Deak, M.; Alessi, D. R.; van-Aalten, D. M. High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-triphosphate. Curr. Biol. 2002, 12, 1256-1262.
57. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Burford, D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nature Struc. Biol. 2002, 9, 940-944.
58. Yang, J.; Cron, P.; Thompson, V.; Good, V. M.; Hess, D.; Hemmings, B. A.; Barford, D. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Molecular Cell 2002, 9, 1227-1240.
59. Scapin, G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today 2002, 7, 601-611.
60. Garcia Echeverria, C.; Traxler, P.; Evans, D. B. ATP site-directed competitive and irreversible inhibitors of protein kinases. Medici. Res. Rev. 2000, 20, 28-57.
61. Noble, M. E. M.; Endicott, J. A.; Johnson, L. N. Protein Kinase Inhibitors: Insights into Drug Design from Structure. Science 2004, 303, 1800-1805.
62. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62, 4236-4243.
63. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289, 1938-1942.
64. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Struc. Biol. 2002, 9 (4), 268-272.
65. Manley, P. W.; Bold, G.; Bruggen, J.; Fendrich, G.; Furet, P.; Mestan, J.; Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, J. Advances in the structural biology, VEGF-R kinase inhibitors for design and clinical development of the treatment of angiogenesis. Bio. Et Biophys. Acta Prot. Proteom. 2004, 1697 (1-2) Special Iss. SI, 17-27.
66. Alessi, D. R.; James, S. R.; Downes, C. P.; Holmes, A. B.; Gaffney, P. R. J.; Reese, C. B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Cur. Biol. 1997, 7, 261-269.
67. Stokoe, D.; Stephens, L. R., Copeland, T.; Gaffney, P. R. J.; Reese, C. B.; Painter, G. F.; Holmes, A. B.; McCormick, F.; Hawkins, P. T. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277, 567-570.
68. Li, Q.; Zhu, G. D. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Top. Med. Chem. 2002, 2, 939-971.
69. Breitenlechner, C. B.; Wegge, T.; Berillon, L.; Graul, K.; Marzenell, K.; Friebe, W. G.; Thomas, U.; Schumacher, R.; Huber, R.; Engh, R. A.; Masjost, B. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem. 2004, 47, 1375-1390.
70. Chijiwa, T.; Mishima, A.; Hagiwara, M.; Sano, M.; Hayashi, K.; Inoue, T.; Naito, K.; Toshioka, T.; Hidaka, H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 1990, 265, 5267-5272.
71. Reuveni, H.; Livnah, N.; Geiger, T.; Klein, S.; Ohne, O.; Cohen, I.; Benhar, M.; Gellerman, G.; Levitzki, A. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 2002, 41, 10304-10314.
72. Garrett, M.D. Eur, J. Cancer Suppl. [16th EORTC-NCI-AACR Symp. Mol. Targets Cancer Ther. (Sept 28-Oct 1, Geneva) 2004] 2004, 2(8), Abst 322).
73. Gills, J. J.; Dennis, P. A. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin. Invest. Drugs 2004 13, 787-797.
74. Powis, G.; Aksoy, I. A.; Melder, D. C.; Aksoy, S.; Eichinger, H.; Fauq, A. H.; Kozikowski, A. P. D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth. Cancer Chemo. Pharmacol. 1991, 29, 95-104.
75. Kozikowski, A. P,; Kiddle, J. J.; Frew, T.; Berggren, M.; Powis, G. Synthesis and biology of 1D-3-deoxyphosphatidylinositol: a putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation. J. Med. Chem. 1995 38, 1053-1056.
76. Qiao, L.; Nan, F.; Kunkel, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J. Med. Chem. 1998, 41 3303-3306.
77. Castillo, S. S.; Brognard, J.; Petukhov, P. A.; Zhang, C. Y.; Tsurutani, J.; Granville, C. A.; Li, M.; Jung, M.; West, K. A.; Gills, J. G.; Kozikowski, A. P.; Dennis, P. A. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res. 2004, 64, 2782-2792.
78. Alfaro-Lopez, J.; Yuan, W.; Phan, B. C.; Kamath, J.; Lou, Q.; Lam, K. S.; Hruby, V. J. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. J. Med. Chem. 1998, 41, 2252-2260.
79. Harris, T. E.; Persaud, S. J.; Saermark, T.; Jones, P. M. Effects of myristoylated pseudosubstrate protein kinase C peptide inhibitors on insulin secretion. Biochem. Soc. Trans. 1995, 23.
80. Luo, Y.; Smith, R. A.; Guan, R.; Liu, X. S.; Klinghofer, V.; Shen, J. W.; Hutchins, C.; Richardson, P.; Holzman, T.; Rosenberg, S. H.; Giranda, V. L. Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 2004, 43, 1254-1263.
81. Livnah, N. L.; Yechezkel, T.; Salitra, Y.; Perlmutter, B.; Ohne, O.; Cohen, I.; Litman, P.; Senderowitz, H. WO2003/010281.
82. Yang, L.; Dan, H. C.; Sun, M.; Liu, Q. Y,; Sun, X. M.; Feldman, R. I.; Hamilton, A. D.; Polokoff, M.; Nicosia, S. V.; Herlyn, M.; Sebti, S. M.; Cheng, J. Q.; Castillo, S. S.; Brognard, J.; Petukhov, P. A.; Zhang, C.; Tsurutani, J.; Granville, C. A.; Li, M.; Jung, M.; West, K. A.; Gills, J. G.; Kozikowski, A. P.; Dennis, P. A. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004, 64, 4394-4399.
83. Feun, L. G.; Blessing, J. A.; Barrett, R. J.; Hanjani, P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am. J. Clin. Oncol. 1993, 16, 506-508.
84. Feun, L. G.; Savaraj, N.; Bodey, G. P.; Lu, K.; Yap, B. S.; Ajani, J. A.; Burgess, M. A.; Benjamin, R. S.; McKelvey, E.; Krakoff, I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 1984, 44, 3608-3612.
85. Jong, L.; Chao, W. R.; Amin, K.; Laderoute, K.; Orduna, J.; Rice, G. SR13668: A novel natural indole derivative potently suppresses tumor growth and inhibits phospho-Akt both in vitro and in vivo Clin. Cancer Res. 2003, 9, 16.
86. Zinda, M. J.; Johnson, M. A.; Paul, J. D.; Horn, C.; Konicek, B. W.; Lu, Z. H.; Sandusky, G.; Thomas, J. E.; Neubauer, B. L.; Lai, M. T.; Graff, J. R. AKT-1,-2, and-3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin. Cancer Res. 2001, 7 (8), 2475-2479.
87. Hsu, J. H.; Shi, Y.; Hu, L.; Fisher, M.; Franke, T. F.; Lichtenstein, A. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene 2002, 21, 1391-1400.
88. Brognard, J.; Clark, A. S.; Ni, Y.; Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61, 3986-3997.
89. Kozikowski, A. P.; Sun, H.; Brognard, J.; Dennis, P. A. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J. Am. Chem. Soc. 2003, 125 1144-1145.
90. Graff, J. R. Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin. Ther. Targets 2002, 6, 103-113.
91. Yang, Z. Z.; Tschopp, O.; Baudry, A.; Dummler, B.; Hynx, D.; Hemmings, B. A. Physiological functions of protein kinase B/Akt. Biochem. Soc. Trans. 2004, 32, 350-354.
92. Defeo-Jones, D.; Barnett, S. F.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Leander, K. R.; McAvoy, E M.; Robinson, R. G.; Duggan, M. E.; Lindsley, C. W.; Zhao, Z.; Huber, H. E.; Jones, R. E. Tumor Cell Sensitization to Apoptotic Stimuli by Selective Inhibition of Specific Akt/PKB Family Members. Mol. Cancer Ther. in press.
93. Barnett, S. F.; Defeo-Jones, D.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Jones, R. E.; Kahana, J. A.; Kral, A.; Leander, K.; Lee, L. L.; Malinowski, J.; McAvoy, E. M.; Nahas, D. D.: Robinson, R.; Huber, H. E. Identification and Characterization of Pleckstrin Homology Domain Dependent and Isozyme Specific Akt Inhibitors. Biochem. J. in press.
94. Lindsley, C. W.; Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E. Allosteric Akt (PKB) Kinase Inhibitors: Discovery and SAR of Isozyme Selective Inhibitors. Bioorg. Med Chem. Lett. in press.
95. Davidson, W.; Frego, L.; Peet, G. W.; Kroe, R. R.; Labadia, M. E.; Lukas, S. M.; Snow, R. J.; Jakes, S.; Grygon, C. A.; Pargellis, C.; Werneburg, B. G. Discovery and characterization of a substrate selective p38alpha inhibitor. Biochemistry 2004, 43, 11658-11671.
96. Alessi, D. R.; Cuenda, A.; Cohen, P.; Dudley, D. T.; Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 1995, 270 (46), 27489-27494.
97. Dudley, D. T.; Pang, L.; Decker, S. J.; Bridges, A. J.; Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 1995, 92, 7686-7689.
98. Favata, M. F.; Horiuchi, K. Y.; Manus, E. J.; Daulerio, A. J.; Stradley, D. A.; Feeser, W. S.; VanDyk, D. E.; Pitts, W. J.; Earl, R. A.; Hobbs, F.; Copeland, R. A.; Magolda, R. L.; Scherle, P. A.; Trzaskos, J. M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998, 273 (29), 18623-18632.
99. Nesterov, A.; Lu, X.; Johnson, M.; Miller, G. J.; Ivashchenko, Y.; Kraft, A. S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 2001, 276, 10767-10774.
100. Rokhlin, O. W.; Guseva, N. V.; Tagiyev, A. F.; Glover, R. A.; Cohen, M. B. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 2002, 52 (1), 1-11.
101. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A Specific Inhibitor of Phosphatidylnositol 3-Kinase, 2-(4-Morpholinyl)-8-Phenyl-4h-1-Benzopyran-4-One (Ly294002). J. Biol. Chem. 1994, 269, 5241-5248.
102. Lindsley, C. W.; Zhao, Z.; Leister, W. H. Fluorous-Tethered Quenching Reagents for Solution Phase Parallel Synthesis. Tetrahedron Lett. 2002, 43, 4225.
103. Patchett, A. A.; Nargund, R. P.; Breitenlechner, C. B.; Wegge, T.; Berillon, L.; Grant, K.; Marzenell, K.; Friebe, W. G.; Thomas, U.; Schumacher, R.; Huber, R.; Engh, R. A.; Masjost, B. Privileged structures - An update: Structure-based optimization of novel azepane derivatives as PKB inhibitors. An. Repor. Medici. Chem. Vol 35 2000, VOL 35, 289-298.
104. Zhao, Z. J.; Leister, W. H.; Strauss, K. A.; Wisnoski, D. D.; Lindsley, C. W. Broadening tile scope of 1,2,4-triazine synthesis by the application of microwave technology. Tetrahedron Lett. 2003, 44, 1123-1127.
105. Wolkenberg, S. E.; Wisnoski, D. D.; Leister, W. H.; Wang, Y.; Zhao, Z. J.; Lindsley, C. W. Efficient synthesis of imidazoles from aldehydes and 1,2-diketones using microwave irradiation. Organic Lett. 2004, 6, 1453-1456.
106. Zhao, Z. J.; Wisnoski, D. D.; Wolkenberg, S. E.; Leister, W. H.; Wang, Y.; Lindsley, C. W. General microwave-assisted protocols for the expedient synthesis of quinoxalines and heterocyclic pyrazines. Tetrahedron Lett. 2004, 45, 4873-4876.
107. Leister, W.; Strauss, K.; Wisnoski, D.; Zhao, Z. J.; Lindsley, C. Development of a custom high-throughput preparative liquid chromatography/mass spectrometer ptatform for the preparative purification and analytical analysis of compound libraries. J. Combina. Chem. 2003, 5, 322-329.